PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET
Company Participants
Tom Johnson – LifeSci AdvisorsFrank Bedu-Addo – CEOKirk Shepard – Chief Medical OfficerLars Boesgaard – CFO
Conference Call Participants
Joseph Pantginis – H.C. WainwrightMayank Mamtani – B. Riley SecuritiesJames Molloy – Alliance Global Partners
Operator
Good morning. And welcome to PDS Biotech’s Fourth Quarter and Full Year 2024 Earnings Conference Call. [Operator Instructions]
At this time, I would now like to turn the conference over to Tom Johnson of LifeSci Advisors. Please go ahead, sir.
Tom Johnson
Thank you, operator. Good morning, everyone. And welcome to PDS Biotech’s 2024 results and clinical program update call.
I am joined on the call today by the following members of the company’s management team. Dr. Frank Bedu-Addo, Chief Executive Officer; Dr. Kirk Shepard, Chief Medical Officer; and Lars Boesgaard, Chief Financial Officer. Dr. Bedu-Addo will begin with an overview of the company’s recent progress and it’s clinical development program. Mr. Boesgaard will review the financial results for 2024 fiscal year. And Dr. Shepard will then join the call to help address questions from covering analysts.
As a reminder, during this call we will make forward-looking statements, which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. Any such statements should be considered in conjunction with the cautionary statements in our press releases and risk factors discussed in our filings with the SEC, including our Quarterly Reports on Form 10-Q and Annual Report on Form 10-K, and these cautionary statements made during this call. We assume no obligation to update any of these forward-looking statements or information.
Now I’d like to turn the call over to Dr. Bedu-Addo. Frank?
Frank Bedu-Addo
Thank
